Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TG4001 and Avelumab in HPV-16 Positive Malignancies
NCT03260023Phase 2Active, not recruiting
- Sponsor
- Transgene SA
- Start
- Sep 2017
- Primary completion
- Sep 2024
- Modality
- Gene Editing, Gene Silencing, Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of tipapkinogene sovacivec in malignant neoplasm (2 arms), sponsored by Transgene SA. Primary endpoints: Safety and Tolerability of TG4001 Plus Avelumab at 4 weeks, Overall Response Rate at 2 years and 1 more. Started Sep 2017; status: active, not recruiting.
02
Drugs
tipapkinogene sovacivec
03
Conditions
malignant neoplasm
Beyond the preview
Go deeper on NCT03260023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03260023.